📗 Cite This Artifact
AAV Gene Therapy for Neurodegeneration — Investment Landscape
AAV Gene Therapy for Neurodegeneration — Investment Landscape
Overview
AAV Gene Therapy for Neurodegeneration — Investment Landscape
Overview
AAV (Adeno-Associated Virus) gene therapy represents one of the most promising approaches for treating neurodegenerative . By delivering therapeutic genes directly to the brain, AAV vectors can potentially restore missing , reduce toxic aggregates, or modulate dysfunctional pathways["@mendell2020"].
Market Size and Growth
| Metric | Value |
|--------|-------|
| Global AAV Gene Therapy Market (2024) | $4.2B |
| Projected Market Size (2030) | $12.8B |
| CAGR | 20.4% |
Clinical Pipeline
Alzheimer's Disease
| Therapy | Company | Phase | Target | Status |
|---------|---------|-------|--------|--------|
| AAV-BR1-[APP](/entities/app-protein) | Lexeo Therapeutics | Preclinical | APP reduction | IND-enabling |
| AAV-[GFAP](/entities/gfap) | Various | Research | APOE4 modulation | Preclinical |
Parkinson's Disease
| Therapy | Company | Phase | Target | Status |
|---------|---------|-------|--------|--------|
| AAV2-GAD | Neurologix | Phase 2 | GAD expression | Completed |
| AAV-AADC | Roche/PTC | Phase 1/2 | AADC expression | Ongoing |
| AAV-NTN1 | Prevail Therapeutics | Phase 1/2 | Neurturin | Completed |
Amyotrophic Lateral Sclerosis
| Therapy | Company | Phase | Target | Status |
|---------|---------|-------|--------|--------|
| AAV-Microdystrophin | Various | Preclinical | DMD gene | Research |
| AAV-GR-N program | Various | Preclinical | Gene silencing | IND-enabling |
Other Indications
| Therapy | Company | Phase | Target | Status |
|---------|---------|-------|--------|--------|
| AAV-RPGR | MeiraGTx | Phase 1/2 | RPGR (eye/brain) | Ongoing |
| AAV-CNGA3 | Various | Approved | CNGA3 (eye) | Approved |
Investment Trends
Recent Funding Rounds
| Company | Round | Amount | Year | Focus |
|---------|-------|--------|------|-------|
| Prevail Therapeutics | Series B | $75M | 2020 | PD |
| Lexeo Therapeutics | Series A | $85M | 2021 | AD |
| Spark Therapeutics | Acquisition | $4.3B | 2019 | Various |
| Neurocrine Biosciences | Partnership | $1.1B | 2023 | CNS |
Key Investors
- OrbiMed: Multiple AAV pipeline investments
- Alexandria Venture Investments: CNS therapeutics focus
- The Column Group: Biotechnology
- ARCH Venture Partners: Gene therapy platform companies
Technology Platforms
AAV Serotypes
| Serotype | Tissue Tropism | Clinical Use |
|----------|---------------|--------------|
| AAV9 | CNS, Heart | Primary choice for brain delivery |
| AAV2 | [Neurons](/entities/neurons) | Historical, well-characterized |
| AAV1 | Muscle, CNS | Preclinical |
| AAV-PHP.B | CNS (high) | Research, limited clinical |
Manufacturing Advances
- Suspension cell culture: Scale-up for commercial manufacturing
- Self-complementary vectors: Enhanced transduction efficiency
- Novel capsid engineering: Targeted delivery improvements
- Insect cell systems: Cost reduction (baculovirus/Sf9)
Challenges and Risks
Technical Challenges
Regulatory Challenges
- FDA/EMA approval pathway: Novel vectors require extensive characterization
- CMC requirements: Complex manufacturing
- Long-term follow-up: Required for gene therapy approval
Commercial Challenges
- Pricing: $1-2M per treatment limits access
- Reimbursement: Limited payer acceptance
- Infrastructure: Specialized delivery centers required
Competitive Landscape
Major Players
| Company | Pipeline Focus | Market Position |
|---------|---------------|-----------------|
| Roche/PTC | AADC, CNS | Leading PD gene therapy |
| Novartis | AAV9, Zolgensma | Established gene therapy |
| Pfizer | Multiple | Late-stage pipeline |
| BioMarin | Lysosomal enzymes | First approved AAV (2017) |
Emerging Companies
- Prevail Therapeutics (Acquired by Eli Lilly): Parkinson's, AD
- Lexeo Therapeutics: Alzheimer's, APOE4
- Voyager Therapeutics: [Tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein)
- Spark Therapeutics (Roche): Inherited retinal disease
Investment Recommendations
Priority Areas
Underinvested Areas
- Huntington's disease: Limited AAV programs
- Frontotemporal dementia: Minimal pipeline
- Multiple system atrophy: No clinical-stage AAV programs
Key Publications
[@mendell2020]: Hinderer C, et al. Adeno-associated virus serotypes for gene delivery to the central nervous system. Molecular Therapy. 2018;26(2):480-492.
[@deverman2018]: Deverman BE, et al. Engineered AAV vectors for CNS gene delivery. Nature Reviews Neuroscience. 2018;19(12):735-748.
Cross-Linking
Related Investment Pages
- [Gene Therapy Investment Landscape](/investment/gene-therapy)
- Alzheimer's Disease Investment Landscape
- Parkinson's Disease Investment Landscape
Related Treatment Pages
- AAV Gene Therapy for Neurodegeneration
- Gene Therapy Overview
Related Mechanism Pages
- AAV Vector Biology
- Gene Delivery
See Also
- [//overview|Cell Types Overview](/content/cell-types)
- [Gene Overview](/genes)
- [//overview|Disease Overview](/diseases/neurodegeneration)
External Links
- [ClinicalTrials.gov
- Gene Therapy Clinical Trials
- PubMed](/diseases/amyotrophic-lateral-sclerosis)## References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | investment-aav-gene-therapy |
| kg_node_id | None |
| entity_type | investment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-1db66bc321a7 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'investment-aav-gene-therapy'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-investment-aav-gene-therapy?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[AAV Gene Therapy for Neurodegeneration — Investment Landscape](http://scidex.ai/artifact/wiki-investment-aav-gene-therapy)
http://scidex.ai/artifact/wiki-investment-aav-gene-therapy